Home/Filings/4/0001209191-19-024478
4//SEC Filing

Walsh Jeffrey T. 4

Accession 0001209191-19-024478

CIK 0001293971other

Filed

Apr 11, 8:00 PM ET

Accepted

Apr 12, 4:17 PM ET

Size

11.1 KB

Accession

0001209191-19-024478

Insider Transaction Report

Form 4
Period: 2019-04-10
Walsh Jeffrey T.
Chief Operating Officer
Transactions
  • Exercise/Conversion

    Stock Option (right to buy)

    2019-04-101,50013,021 total
    Exercise: $24.47Exp: 2024-03-03Common Stock (1,500 underlying)
  • Sale

    Common Stock

    2019-04-10$156.44/sh1,100$172,08541,321 total
  • Exercise/Conversion

    Common Stock

    2019-04-10$24.47/sh+1,500$36,70542,421 total
  • Sale

    Common Stock

    2019-04-10$157.23/sh400$62,89140,921 total
Footnotes (4)
  • [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 2, 2018.
  • [F2]The range of prices for the transaction reported on this line was $156.09 to $156.62. The average weighted price was $156.4409. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
  • [F3]The range of prices for the transaction reported on this line was $157.09 to $157.38. The average weighted price was $157.2275. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
  • [F4]This option vested over a four-year period, at a rate of twenty-five percent (25%) on January 1, 2015 and in 36 equal monthly installments thereafter.

Issuer

bluebird bio, Inc.

CIK 0001293971

Entity typeother

Related Parties

1
  • filerCIK 0001578251

Filing Metadata

Form type
4
Filed
Apr 11, 8:00 PM ET
Accepted
Apr 12, 4:17 PM ET
Size
11.1 KB